Radiation oncologist who showed a blood test can detect leftover lung cancer months before scans.
Maximilian Diehn is Professor of Radiation Oncology at Stanford University, within the Stanford Cancer Institute. A radiation oncologist and physician-scientist specialising in circulating tumour DNA and lung cancer, he co-developed CAPP-Seq with Ash Alizadeh and demonstrated ctDNA-based detection of minimal residual disease after curative lung cancer treatment, showing a blood test can find leftover cancer months before scans. His papers include the Cancer Discovery report on early detection of molecular residual disease in localised lung cancer by ctDNA profiling and a Nature study integrating genomic features for non-invasive early lung cancer detection. He also studies radiation biology, personalised radiotherapy and stereotactic techniques in non-small-cell lung cancer.
| Title | Journal | Year |
|---|---|---|
| Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling | Cancer Discovery | 2017 |
| Integrating genomic features for non-invasive early lung cancer detection | Nature | 2020 |
Shares Stanford Health Care / Stanford Cancer Institute, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Non-small-cell lung cancer.
Shares SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer.
Shares SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer.
Shares SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer.